Paclitaxel shows cytotoxic activity in human hepatocellular carcinoma cell lines

Cancer Letters

Volumn 136, Issue 1, 1999, Pages 109-118

  Gagandeep, Singh ^a   Novikoff, Phyllis M ^a   Ott, Michael ^a   Gupta, Sanjeev ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Carcinoma cells; Flow cytometry; Hepatocellular; Paclitaxel

Indexed keywords

PACLITAXEL; VERAPAMIL;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL CYCLE; CELL STRAIN HEPG2; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; LIVER CELL CARCINOMA; PRIORITY JOURNAL;

ADOLESCENT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; DRUG SYNERGISM; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY TUBULES; LIVER NEOPLASMS; MALE; PACLITAXEL; THYMIDINE; TUMOR CELLS, CULTURED; VERAPAMIL;

EID: 0032996680     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(98)00388-7     Document Type: Article

References (33)

1. Aden D.P., Fogel A., Plotkin S., Damjanov I., Knowles B.B. Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature. 282:1979;615-616.
2. Bhalla K., Huang Y., Tang C., et al. Characterization of a human myeloid leukemia cell line highly resistant to taxol. Leukemia. 8:1994;465-475.
3. Braunstein J.D., Schulze D., DelGuidice T., Furst T., Schildkraut C.L. The temporal order of replication of murine immunoglubulin heavy chain constant region sequences corresponds to their linear order in the genome. Nucl. Acids Res. 10:1982;6887-6902.
4. Chang Y.F., Li L.L., Liu T.Y., Lui W.Y., P'eng F.K., Chi C.W. Paclitaxel induced apoptosis in human gastric carcinoma cell lines. Cancer. 77:1996;14-18.
5. Cresteil T., Monsarrat B., Alvinerie P., Treluyer J.M., Vierra I., Wright M. Taxol metabolism by liver microsomes: identification of cytochrome p450 isozymes involved in its biotransformation. Cancer Res. 54:1994;386-392.
6. Denizot F., Lang R. Rapid calorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J. Immunol. Methods. 89:1986;271-277.
7. Donaldson K.L., Goolsby G.L., Kiener P.A., Wahl A.F. Activation of p34cdc2 coincident with taxol-induced apoptosis. Cell Growth Diff. 5:1994;1041-1050.
8. Drori S., Eytan G.D., Assaraf Y.G. Potentiation of anticancer-drug cytotoxicity by multidrug-resistance chemosensitizers involves alterations in membrane fluidity leading to increased membrane permeability. Eur. J. Biochem. 228:1995;1020-1029.
9. Duke R.C., Cohen J.J. Morphological and biochemical assays of apoptosis. Coligan J.E., Kruisbeek, Margulies D.H., Shevack E.M., Strober W. Current Protocols in Immunology. 1992;3.17.1 Wiley, New York.
10. Fukuda I., Ogawa K. Detection of p53 gene mutations in rat hepatocellular carcinomas cell lines by denaturing gradient gel electrophoresis. Mol. Carcinogen. 7:1993;257-262.
11. Gupta S., LaBrecque D.R., Shafritz D.A. Mitogenic effects of hepatic stimulator substance on cultured non-parenchymal liver epithelial cells. Hepatology. 15:1992;485-491.
12. Gupta S., Shafritz D.A. Viral mechanisms in hepatic oncogenesis. Arias I.M., Boyer J.L., Fausto N., Jakoby W.B., Schachter D., Shafritz D.A. Liver Biology and Pathobiology. third ed. 1994;1429 Raven Press, New York.
13. Jordan M.A., Wendell K., Gardiner S., Derry W.B., Copp H., Wilson L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel results in abnormal mitotic exit and apoptotic cell death. Cancer Res. 56:1996;816-825.
14. Koechli O.R., Sevin B.U., Perras J.P., Chou T.C., Angioloi R., Steren A., Untch M., Averette H.E. Characteristics of the combination of paclitaxel plus doxorubicin in breast cancer cell lines analyzed with ATP-cell viability assay. Breast Cancer Res. Treat. 28:1993;21-27.
15. Kress S., Konig J., Schweizer J., Lohrke H., Bauer-Hofman R., Schwarz M. p53 mutations are absent from carcinogen-induced mouse liver tumors but occur in cell lines established from these tumors. Mol. Carcinogen. 6:1992;148-158.
16. Labarca C., Paigen K. A simple; rapid and sensitive DNA assay procedure. Anal. Biochem. 102:1980;344-352.
17. Liebmann J.E., Cook J.A., Lipschultz C., Teague D., Fisher J., Mitchell J.B. Cytotoxic studies of paclitaxel in human tumor cell lines. Br. J. Cancer. 68:1993;1104-1109.
18. MacLachlan T.K., Sang N., Giordano A. Cyclins; cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer. Crit. Rev. Eukaryot. Gene Expr. 5:1995;127-156.
19. Murakami Y. Co-activation of p53 and Rb genes in human hepatocellular carcinoma. Nippon Rinsho. 51:1993;375-379.
20. Nakabayashi H., Taketa K., Miyano K., Yamane T., Sato J. Growth of human hepatoma cell lines with differentiated functions in chemically defined medium. Cancer Res. 42:1982;3858-3863.
21. Novikoff P.M., Cammer M., Tao L., Oda H., Stockert R.J., Wolkoff A.W., Satir P. Three-dimensional organization of rat hepatocyte cytoskeleton: relation to the asialoglycoprotein pathway. J. Cell Sci. 109:1996;21-32.
22. Rao K.V., Hanuman J.B., Alvarez C., Stoy M., Juchum J., Davies R.M., Baxley R. A new large scale process for taxol and related taxanes from Taxus brevifolia. Pharm. Res. 12:1995;1003-1010.
23. Rao S., Orr G.A., Chaudhary A.G., Kingston D.G., Horwitz S.B. Characterization of taxol binding site on the microtubule. 2-(M-Azidobenzoyl) taxol photolabels a peptide (amino acids 217-231) of beta-tubulin. J. Biol. Chem. 270:1995;20235-20238.
24. SEER Cancer Statistics Review; 1973-1991: Tables and Graphs. Ries L.A.G., Miller B.A., Hankey B.F., Kosar C.L., Harras A., Edwards B.K. 1994;250 National Cancer Institute, Bethesda.
25. Rowinsky E.K., Burke P.J., Karp J.E., Tucker R.W., Ettinger D.S., Donehower R.C. Phase I and pharmacodynamic study of taxol in refractory acute leukemias. Cancer Res. 49:1989;4640-4647.
26. Rowinsky E.K., Gilbert M.R., McGuire W.P., et al. Sequences of Taxol and cisplatin: a phase I and pharmacologic study. J. Clin. Oncol. 9:1991;1692-1703.
27. Schiff P.B., Fant J., Horwitz S.B. Promotion of microtubule assembly in vitro by paclitaxel. Nature. 277:1979;665-667.
28. Schiff P.B., Horwitz S.B. Taxol stabilizes microtubules in mouse fibroblasts. Proc. Natl. Acad. Sci. USA. 77:1980;1561-1565.
29. Tishler R.B., Lamppu D.M., Park S., Price B.D. Microtubule-active drugs taxol; vinblastine and nocodazole increase the levels of transcriptionally active p53. Cancer Res. 55:1995;6021-6025.
30. Untch M., Untch A., Sevin B.U., Angioli R., Perras J.P., Koechli O., Averette H.E. Comparison of paclitaxel. docetaxel in gynecologic and breast cancer cell lines with ATP-cell viability assay. Anticancer Drugs. 5:1994;24-30.
31. Walle T., Kumar G.N., McMillan J.M., Thornburg K.R., Walle U.K. Taxol metabolism in rat hepatocytes. Biochem. Pharmacol. 46:1993;1661-1664.
32. Wang Q., Fan S., Eastman A., Worland P.J., Sausville E.A. O'Connor, P.M., UNC-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J. Natl. Cancer Inst. 88:1996;956-965.
33. Yamamato M., Ogawa K., Makoto M., Fukuda K., Koatsu Y. The herbal medicine inchin-ko-to inhibits liver cell apoptosis induced by transforming growth factor β1. Hepatology. 23:1996;552-559.